Monday, February 27, 2017

Drugs in Clinical Pipeline: AL-3778 I Treatment for Hepatitis B Virus (HBV) | Antivirals Agents


AL-3778 (also known as ALS-003778; JNJ-63595948; NVR-1221; NVR-3-778) is an experimental drug being developed by Alios BioPharma, Inc. to treat Hepatitis B virus infection. Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) which affects the liver. It can cause both acute and chronic infections. The virus is transmitted by exposure to infectious blood or body fluids. Infection around the time of birth or from contact with other people's blood during childhood is the most frequent method by which hepatitis B is acquired in areas where the disease is common. In areas where the disease is rare, intravenous drug use and sexual intercourse are the most frequent routes of infection.

Treatment for Hepatitis B Virus (HBV)
A New Drug for the Treatment for Hepatitis B Virus (HBV)


AL-3778 is currently in pre-clinical studies. It is also in Phase I trials in combination with Entecavir or Tenofovir Disoproxil Fumarate in healthy volunteers [1].

References:
1. ClinicalTrials.gov Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers. NCT03032536
1 2 3